-
Published 10/6/2025
Cournoyer L, Liu Y, Jaroch DB, Hullinger TG, Cox BF, Katz SC, LaPorte J, Layman IB, Ballarin A, Ghosh CC, Guha P. Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models. Front Oncol. 2025; 15:1655794. PMID: 41122641.
-
Published 6/3/2025
Pan K, Vromans AM, Cheng L, Grant-Kels JM, Katz SC, Hadfield MJ. Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets. Curr Oncol Rep. 2025 Jul; 27(7):822-832. PMID: 40459726.
-
Published 11/23/2024
Jaroch DB, Liu Y, Kim AY, Katz SC, Cox BF, Hullinger TG. Pressure-Enabled Drug Delivery Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model. J Vasc Interv Radiol. 2025 Mar; 36(3):499-504.e1. PMID: 39586533.
-
Published 7/22/2024
Ghosh CC, Cournoyer L, Liu Y, Ballarin A, Layman IB, LaPorte J, Morrissey M, Fraser K, Perati S, Cox BF, Yakirevich E, Treaba DO, Murtha TD, Guha P, Katz SC, Davar D. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. J Immunother Cancer. 2024 Jul 22; 12(7). PMID: 39038918.
-
Published 7/3/2024
Jaroch DB, Liu Y, Kim AY, Katz SC, Cox BF, Hullinger TG. Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model. J Vasc Interv Radiol. 2024 Oct; 35(10):1525-1533.e4. PMID: 38969336.